MGI Tech And Eurofins Genomics Unite To Propel Precision Health With Innovative Sequencer

In a significant move for the life sciences sector, MGI Tech, a pioneer in developing core tools and technology for advancing life science, has announced a landmark collaboration with Eurofins Genomics Europe Genotyping A/S ("Eurofins Genomics"). This partnership is marked by Eurofins Genomics' corporate acquisition of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer, alongside the ZTRON Appliance genomics data center and an array of MGI's cutting-edge laboratory automation products and systems. This transaction signifies the first corporate order of the T20 in Europe, heralding a new era in precision health initiatives across the continent.

Dr. Yong Hou, General Manager of MGI Europe and Africa, expressed his excitement about the collaboration, stating, "We are thrilled to work with Eurofins Genomics to leverage T20's ultra-high throughput and remarkable cost-efficiency to empower large population genome projects across the world. With this partnership, we hope to improve accessibility of cost-effective sequencing to researchers globally." The T20 sequencer, powered by MGI's proprietary DNBSEQTM technology, is celebrated for its ability to significantly lower sequencing costs to below $100 per genome for projects sequencing 50,000 WGS per year. This breakthrough has attracted global attention for its potential to make genetic sequencing more accessible and affordable.

Launched in February 2023, the T20 is engineered to tackle the most demanding sequencing scenarios. It supports a broad spectrum of high-throughput sequencing applications in both scientific and clinical research domains, including whole genome sequencing (WGS), whole genome bisulfite sequencing (WGBS), stLFR, single-cell sequencing, Stereo-seq, and more. Its adoption by leading research institutions and healthcare providers worldwide underscores its versatility and efficiency.

Eurofins Genomics, established in 1990 and a part of the Eurofins Scientific Group, is a key player in specialty esoteric and molecular clinical diagnostic testing in Europe and the United States. With laboratories in over 50 countries and a workforce exceeding 55,000 employees, Eurofins Genomics offers an extensive portfolio of over 200,000 analytical methods for assessing biological substances and products. This collaboration between MGI and Eurofins Genomics is poised to enhance genomics research and clinical applications significantly.

About MGI: MGI Tech Co. Ltd., headquartered in Shenzhen, focuses on the research & development, production, and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine, and healthcare. As a leading producer of clinical high-throughput gene sequencers, MGI's multi-omics platforms encompass genetic sequencing, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information about MGI and its innovations in life science technology, please visit their official website or connect with them on Twitter, LinkedIn or YouTube.